Literature DB >> 18433946

Immunization with an HIV-1 immunogen induces CD4+ and CD8+ HIV-1-specific polyfunctional responses in patients with chronic HIV-1 infection receiving antiretroviral therapy.

L Valor1, J Navarro, J Carbone, C Rodríguez-Sáinz, J Gil, F López, E Fernández-Cruz.   

Abstract

Development of polyfunctional T lymphocyte responses is critical in the immunological response against HIV-1. Fifty-four HIV-1 infected patients receiving antiretroviral treatment (ART) and immunization with an HIV-1 immunogen or placebo, periodically every 3 months throughout a period of 36 months, were evaluated for the purposes of analysing the development of HIV-1-specific CD4+ and CD8+ responses. A significant increase of proliferating and IFN-gamma producing CD8+ HIV-1-specific T cells, of HIV-1-specific precursor frequencies for CD8+ and for CD4+ T cells and of Gag/pol-specific memory CTL precursors (CTLp) was observed in the immunogen group in comparison to placebo. IL-2 intracellular expression and IFN-gamma and TNF-alpha co-expression in HIV-1-specific CD8+ T cells were also substantially increased in the immunized group. A negative correlation between viral load and CD3+CD4+CFSElow HIV-1-specific lymphoproliferative response and frequency of Gag/pol-specific CTLp was solely observed in the HIV-1 immunogen group. Long-term immunization in patients receiving ART helps to develop HIV-1-specific polyfunctional T cell responses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18433946     DOI: 10.1016/j.vaccine.2008.03.019

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

Review 1.  ELISpot for measuring human immune responses to vaccines.

Authors:  Meredith Slota; Jong-Baeck Lim; Yushe Dang; Mary L Disis
Journal:  Expert Rev Vaccines       Date:  2011-03       Impact factor: 5.217

2.  Sublingual therapeutic immunization with a polyvalent bacterial preparation in patients with recurrent respiratory infections: immunomodulatory effect on antigen-specific memory CD4+ T cells and impact on clinical outcome.

Authors:  D Alecsandru; L Valor; S Sánchez-Ramón; J Gil; J Carbone; J Navarro; J Rodríguez; C Rodríguez-Sainz; E Fernández-Cruz
Journal:  Clin Exp Immunol       Date:  2011-04       Impact factor: 4.330

3.  Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines.

Authors:  Eric Tran; Julie S Nielsen; Darin A Wick; Alvin V Ng; Lisa D S Johnson; Nancy J Nesslinger; Elissa McMurtrie; John R Webb; Brad H Nelson
Journal:  PLoS One       Date:  2010-12-22       Impact factor: 3.240

4.  Impact of the Polymorphism rs9264942 near the HLA-C Gene on HIV-1 DNA Reservoirs in Asymptomatic Chronically Infected Patients Initiating Antiviral Therapy.

Authors:  Laura Herráiz-Nicuesa; Diana Carolina Hernández-Flórez; Lara Valor; Sonia García-Consuegra; Juan Paulo Navarro-Valdivieso; Eduardo Fernández-Cruz; Carmen Rodríguez-Sainz
Journal:  J Immunol Res       Date:  2017-12-28       Impact factor: 4.818

5.  Induction and maintenance of bi-functional (IFN-γ + IL-2+ and IL-2+ TNF-α+) T cell responses by DNA prime MVA boosted subtype C prophylactic vaccine tested in a Phase I trial in India.

Authors:  Sivasankaran Munusamy Ponnan; Sathyamurthy Pattabiram; Kannan Thiruvengadam; Rajat Goyal; Nikhil Singla; Joyeeta Mukherjee; Shweta Chatrath; Philip Bergin; Jakub T Kopycinski; Jill Gilmour; Sriram Kumar; Malathy Muthu; Sudha Subramaniam; Soumya Swaminathan; Srikanth Prasad Tripathy; Hanna Elizabeth Luke
Journal:  PLoS One       Date:  2019-03-28       Impact factor: 3.240

6.  Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients.

Authors:  Anni A Winckelmann; Lærke V Munk-Petersen; Thomas A Rasmussen; Jesper Melchjorsen; Thomas J Hjelholt; David Montefiori; Lars Østergaard; Ole S Søgaard; Martin Tolstrup
Journal:  PLoS One       Date:  2013-04-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.